<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03890380</url>
  </required_header>
  <id_info>
    <org_study_id>CLP-01</org_study_id>
    <nct_id>NCT03890380</nct_id>
  </id_info>
  <brief_title>Safety and Performance Evaluation of the Magneto Wire</brief_title>
  <official_title>Safety and Performance Evaluation of the Magneto Wire</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Magneto Thrombectomy Solutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Magneto Thrombectomy Solutions</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, open label single arm feasibility study to evaluate the safety and performance
      of the Magneto Wire in patients diagnosed with acute ischemic stroke and planned for
      thrombectomy procedure.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor's decision
  </why_stopped>
  <start_date type="Actual">December 17, 2018</start_date>
  <completion_date type="Actual">October 27, 2019</completion_date>
  <primary_completion_date type="Actual">July 18, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Assessment</measure>
    <time_frame>24 (±8) hours post procedure</time_frame>
    <description>Occurrence of Device-related Serious Adverse Events (SAEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Assessment</measure>
    <time_frame>90 (±10) days</time_frame>
    <description>Occurrence of Device-related Serious Adverse Events (SAEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Revascularization</measure>
    <time_frame>immediate</time_frame>
    <description>Revascularization in the immediate post procedure angiogram, using modified Thrombolysis in Cerebrovascular Infarction (mTIC≥2b)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distal Embolism</measure>
    <time_frame>immediate</time_frame>
    <description>Evidence of Infarction of a previously uninvolved vascular territory in the immediate post procedure angiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institutes of Health Stroke Scale (NIHSS)</measure>
    <time_frame>24 (±8) hours post procedure</time_frame>
    <description>NIHSS scale is used to evaluate the severity of a stroke by assessing the stroke-related neurologic deficit. Scores range from 0-42, a higher score indicates a higher severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale</measure>
    <time_frame>90 (±10) days</time_frame>
    <description>Modified Rankin scale is used to evaluate the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. Scores range from 0-6 (0-no symptoms, 6- death)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Magneto Wire</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with Magneto Wire</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magneto Wire</intervention_name>
    <description>Patients will be treated with Magneto Wire</description>
    <arm_group_label>Magneto Wire</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute ischemic stroke within defined timelines.

          -  Age 18-85 years old

          -  NIHSS ≥ 8

          -  No significant pre-stroke functional disability (mRS ≤ 1)

        Exclusion Criteria:

          -  Life expectancy of less than 90 days

          -  Neurological signs that are rapidly improving prior to or at time of treatment

          -  NIHSS≥30 or state of coma

          -  Ongoing seizure

          -  Current use of cocaine or other vasoactive substance

          -  Known bleeding diathesis

          -  Known hemorrhagic or coagulation deficiency

          -  Evidence of active systemic infection

          -  Current use of oral anticoagulants INR &gt; 3

          -  Administration of heparin or Novel Oral Anticoagulants within 48 hours preceding the
             onset of stroke and have an abnormal aPTT at presentation

          -  Platelet count &lt; 50,000/mm3

          -  Glucose &lt;50 mg/dL (2.8 mmol, 2.6mM)

          -  Uncontrolled hypertension (SBP&gt;185 or DBP&gt;110) refractory to pharmacological
             management

          -  Known hypersensitivity or allergy to radiographic contrast agents

          -  Pregnancy or lactating female

          -  Subject already enrolled in a clinical study involving experimental medication or
             device

          -  CT scan or MRI with evidence of acute intracranial hemorrhage, ASPECT score&lt;6, mass
             effect and/or intracranial tumor.

          -  Angiographic evidence of carotid dissection, or high grade stenosis that will prevent
             access to the clot, or cerebral vasculitis, or intracranial stenosis

          -  Blood vessel with extreme tortuosity or other conditions preventing the access of the
             device.

          -  Angiographic evidence of carotid dissection, complete cervical carotid occlusions or
             vasculitis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shally Sharon</last_name>
    <role>Study Director</role>
    <affiliation>Magneto Thrombectomy Solutions</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 25, 2019</study_first_submitted>
  <study_first_submitted_qc>March 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2019</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

